These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38928449)

  • 1. Bcl-2 Up-Regulation Mediates Taxane Resistance Downstream of APC Loss.
    Wise AR; Maloney S; Hering A; Zabala S; Richmond GE; VanKlompenberg MK; Nair MT; Prosperi JR
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenomatous Polyposis Coli loss controls cell cycle regulators and response to paclitaxel in MDA-MB-157 metaplastic breast cancer cells.
    Astarita EM; Maloney SM; Hoover CA; Berkeley BJ; VanKlompenberg MK; Nair TM; Prosperi JR
    PLoS One; 2021; 16(8):e0255738. PubMed ID: 34370741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts.
    Nocquet L; Roul J; Lefebvre CC; Duarte L; Campone M; Juin PP; Souazé F
    Sci Rep; 2024 Jun; 14(1):14177. PubMed ID: 38898061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y; Yu Y; Li X; Guo A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APC selectively mediates response to chemotherapeutic agents in breast cancer.
    VanKlompenberg MK; Bedalov CO; Soto KF; Prosperi JR
    BMC Cancer; 2015 Jun; 15():457. PubMed ID: 26049416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
    Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
    J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low DEDD expression in breast cancer cells indicates higher sensitivity to the Bcl-2-specific inhibitor ABT-199.
    Liu D; Qin X; Sun Z; Hou S; Lv Q
    Biochem Biophys Res Commun; 2020 May; 525(3):549-556. PubMed ID: 32113682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells.
    Hedayat M; Khezri MR; Jafari R; Malekinejad H; Majidi Zolbanin N
    Med Oncol; 2023 Aug; 40(9):263. PubMed ID: 37548777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
    Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-18a upregulation decreases Dicer expression and confers paclitaxel resistance in triple negative breast cancer.
    Sha LY; Zhang Y; Wang W; Sui X; Liu SK; Wang T; Zhang H
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2201-8. PubMed ID: 27338043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
    Yang X; Zhao L; Pei J; Wang Z; Zhang J; Wang B
    Breast Cancer Res Treat; 2020 Aug; 183(1):71-82. PubMed ID: 32601971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
    Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
    Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
    Yi M; Peng C; Xia B; Gan L
    Clin Breast Cancer; 2022 Feb; 22(2):e191-e198. PubMed ID: 34284965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
    Zhao PW; Cui JX; Wang XM
    Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.